United Therapeutics (UTHR) Stock: Charts & Financials

United Therapeutics Corporation (UTHR)UTHRUnited Therapeutics Corporation

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Total Current Assets	2.87B	2.87B	3.70B	3.49B	3.83B	3.94B	3.87B	4.00B	3.62B
Cash & Cash Equivalents	1.07B	1.07B	1.56B	1.14B	1.59B	1.90B	1.70B	1.55B	1.36B
Short-Term Investments	1.08B	1.08B	0.00	1.63B	1.46B	1.42B	1.57B	1.77B	1.62B
Cash & Short-Term Investments	2.15B	2.15B	1.56B	2.77B	3.05B	3.32B	3.27B	3.33B	2.97B
Accounts Receivable	312.00M	312.00M	350.20M	297.70M	379.30M	322.00M	279.30M	341.80M	290.70M
Inventory	178.30M	178.30M	183.10M	176.50M	169.20M	165.40M	157.90M	146.70M	136.50M
Total Assets	6.71B	6.71B	7.88B	7.35B	7.91B	7.74B	7.36B	7.12B	6.72B
Property, Plant & Equipment	1.84B	1.84B	1.73B	1.56B	1.36B	1.30B	1.22B	1.16B	1.09B
Goodwill	0.00	0.00	0.00	0.00	0.00	0.00	32.30M	0.00	0.00
Intangible Assets	115.50M	115.50M	116.50M	116.70M	111.50M	111.70M	79.60M	112.10M	115.20M
Long-Term Investments	1.41B	1.41B	1.78B	1.66B	1.92B	1.71B	1.48B	1.28B	1.33B
Total Current Liabilities	599.10M	599.10M	560.60M	546.30M	527.10M	721.50M	738.10M	873.40M	832.30M
Accounts Payable	498.30M	498.30M	7.10M	468.00M	432.00M	367.00M	6.00M	363.90M	325.30M
Short-Term Debt	0.00	0.00	0.00	0.00	0.00	200.00M	300.00M	400.00M	400.00M
Total Liabilities	813.10M	813.10M	783.80M	760.90M	734.40M	936.70M	920.00M	1.02B	1.03B
Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00M
Total Debt	0.00	0.00	37.60M	0.00	0.00	200.00M	300.00M	400.00M	500.00M
Net Debt (Cash)	-1.07B	-1.07B	-1.52B	-1.14B	-1.59B	-1.70B	-1.40B	-1.15B	-855.70M
Total Shareholders' Equity	5.90B	5.90B	7.10B	6.59B	7.17B	6.81B	6.44B	6.10B	5.70B
Common Stock	800K	800K	800K	800K	800K	800K	800K	700K	700K
Retained Earnings	8.83B	8.83B	8.56B	8.19B	7.85B	7.54B	7.22B	6.92B	6.61B
Current Ratio	4.79	4.79	6.60	6.40	7.26	5.46	5.25	4.58	4.35
Debt to Equity Ratio	0.00	0.00	0.01	0.00	0.00	0.03	0.05	0.07	0.09

Quarterly Report

TTM

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Quarter ended Jun 2024

Total Current Assets

2.87B

3.70B

3.49B

3.83B

3.94B

3.87B

4.00B

3.62B

Cash & Cash Equivalents

1.07B

1.56B

1.14B

1.59B

1.90B

1.70B

1.55B

1.36B

Short-Term Investments

1.08B

0.00

1.63B

1.46B

1.42B

1.57B

1.77B

1.62B

Cash & Short-Term Investments

2.15B

1.56B

2.77B

3.05B

3.32B

3.27B

3.33B

2.97B

Accounts Receivable

312.00M

350.20M

297.70M

379.30M

322.00M

279.30M

341.80M

290.70M

Inventory

178.30M

183.10M

176.50M

169.20M

165.40M

157.90M

146.70M

136.50M

Total Assets

6.71B

7.88B

7.35B

7.91B

7.74B

7.36B

7.12B

6.72B

Property, Plant & Equipment

1.84B

1.73B

1.56B

1.36B

1.30B

1.22B

1.16B

1.09B

Goodwill

0.00

32.30M

0.00

Intangible Assets

115.50M

116.50M

116.70M

111.50M

111.70M

79.60M

112.10M

115.20M

Long-Term Investments

1.41B

1.78B

1.66B

1.92B

1.71B

1.48B

1.28B

1.33B

Total Current Liabilities

599.10M

560.60M

546.30M

527.10M

721.50M

738.10M

873.40M

832.30M

Accounts Payable

498.30M

7.10M

468.00M

432.00M

367.00M

6.00M

363.90M

325.30M

Short-Term Debt

0.00

200.00M

300.00M

400.00M

Total Liabilities

813.10M

783.80M

760.90M

734.40M

936.70M

920.00M

1.02B

1.03B

Long-Term Debt

0.00

100.00M

Total Debt

0.00

37.60M

0.00

200.00M

300.00M

400.00M

500.00M

Net Debt (Cash)

-1.07B

-1.52B

-1.14B

-1.59B

-1.70B

-1.40B

-1.15B

-855.70M

Total Shareholders' Equity

5.90B

7.10B

6.59B

7.17B

6.81B

6.44B

6.10B

5.70B

Common Stock

800K

700K

Retained Earnings

8.83B

8.56B

8.19B

7.85B

7.54B

7.22B

6.92B

6.61B

Current Ratio

4.79

6.60

6.40

7.26

5.46

5.25

4.58

4.35

Debt to Equity Ratio

0.00

0.01

0.00

0.03

0.05

0.07

0.09

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	3.70B	3.87B	3.55B	3.38B	2.32B	2.17B	1.86B	1.77B
Cash & Cash Equivalents	1.56B	1.70B	1.21B	961.20M	894.80M	738.70M	738.40M	669.20M
Short-Term Investments	0.00	1.57B	1.79B	1.88B	1.04B	1.10B	747.50M	746.70M
Cash & Short-Term Investments	1.56B	3.27B	2.99B	2.84B	1.93B	1.83B	1.49B	1.42B
Accounts Receivable	350.20M	279.30M	278.90M	220.40M	198.70M	157.40M	151.40M	175.70M
Inventory	183.10M	157.90M	111.80M	102.00M	93.80M	86.50M	93.40M	101.00M
Total Assets	7.88B	7.36B	7.17B	6.04B	5.17B	4.62B	3.91B	3.40B
Property, Plant & Equipment	1.73B	1.22B	1.05B	861.50M	780.90M	731.60M	738.50M	699.70M
Goodwill	0.00	32.30M	33.70M	28.00M	28.00M	28.00M	28.00M	31.50M
Intangible Assets	116.50M	79.60M	80.50M	16.50M	16.60M	130.10M	130.30M	139.30M
Long-Term Investments	1.78B	1.48B	1.91B	1.32B	1.65B	1.15B	767.50M	442.60M
Total Current Liabilities	560.60M	738.10M	804.40M	343.20M	305.40M	323.30M	463.00M	276.60M
Accounts Payable	7.10M	6.00M	5.60M	4.10M	3.80M	4.10M	9.90M	23.10M
Short-Term Debt	0.00	300.00M	400.00M	0.00	0.00	0.00	250.00M	0.00
Total Liabilities	783.80M	920.00M	1.18B	1.25B	1.21B	1.22B	1.13B	612.40M
Long-Term Debt	0.00	0.00	300.00M	800.00M	800.00M	800.00M	600.00M	250.00M
Total Debt	37.60M	300.00M	700.00M	800.00M	800.00M	800.00M	850.00M	250.00M
Net Debt (Cash)	-1.52B	-1.40B	-507.70M	-161.20M	-94.80M	61.30M	111.60M	-419.20M
Total Shareholders' Equity	7.10B	6.44B	5.98B	4.80B	3.96B	3.40B	2.78B	2.79B
Common Stock	800K	800K	700K	700K	700K	700K	700K	700K
Retained Earnings	8.56B	7.22B	6.03B	5.04B	4.32B	3.84B	3.33B	3.43B
Current Ratio	6.60	5.25	4.41	9.85	7.61	6.70	4.03	6.39
Debt to Equity Ratio	0.01	0.05	0.12	0.17	0.20	0.24	0.31	0.09

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Total Current Assets

3.70B

3.87B

3.55B

3.38B

2.32B

2.17B

1.86B

1.77B

Cash & Cash Equivalents

1.56B

1.70B

1.21B

961.20M

894.80M

738.70M

738.40M

669.20M

Short-Term Investments

0.00

1.57B

1.79B

1.88B

1.04B

1.10B

747.50M

746.70M

Cash & Short-Term Investments

1.56B

3.27B

2.99B

2.84B

1.93B

1.83B

1.49B

1.42B

Accounts Receivable

350.20M

279.30M

278.90M

220.40M

198.70M

157.40M

151.40M

175.70M

Inventory

183.10M

157.90M

111.80M

102.00M

93.80M

86.50M

93.40M

101.00M

Total Assets

7.88B

7.36B

7.17B

6.04B

5.17B

4.62B

3.91B

3.40B

Property, Plant & Equipment

1.73B

1.22B

1.05B

861.50M

780.90M

731.60M

738.50M

699.70M

Goodwill

0.00

32.30M

33.70M

28.00M

31.50M

Intangible Assets

116.50M

79.60M

80.50M

16.50M

16.60M

130.10M

130.30M

139.30M

Long-Term Investments

1.78B

1.48B

1.91B

1.32B

1.65B

1.15B

767.50M

442.60M

Total Current Liabilities

560.60M

738.10M

804.40M

343.20M

305.40M

323.30M

463.00M

276.60M

Accounts Payable

7.10M

6.00M

5.60M

4.10M

3.80M

4.10M

9.90M

23.10M

Short-Term Debt

0.00

300.00M

400.00M

0.00

250.00M

0.00

Total Liabilities

783.80M

920.00M

1.18B

1.25B

1.21B

1.22B

1.13B

612.40M

Long-Term Debt

0.00

300.00M

800.00M

600.00M

250.00M

Total Debt

37.60M

300.00M

700.00M

800.00M

850.00M

250.00M

Net Debt (Cash)

-1.52B

-1.40B

-507.70M

-161.20M

-94.80M

61.30M

111.60M

-419.20M

Total Shareholders' Equity

7.10B

6.44B

5.98B

4.80B

3.96B

3.40B

2.78B

2.79B

Common Stock

800K

700K

Retained Earnings

8.56B

7.22B

6.03B

5.04B

4.32B

3.84B

3.33B

3.43B

Current Ratio

6.60

5.25

4.41

9.85

7.61

6.70

4.03

6.39

Debt to Equity Ratio

0.01

0.05

0.12

0.17

0.20

0.24

0.31

0.09

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)